Please use this identifier to cite or link to this item:
Title: A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART
Author: Gómez, Carmen Elena
Perdiguero, Beatriz
García Arriaza, Juan
Cepeda, Victoria
Sánchez Sorzano, Carlos Oscar
Mothe, Beatriz
Jiménez, José Luis
Muñoz Fernández, María Ángeles
Gatell, José M
López Bernaldo de Quirós, Juan Carlos
Brander, Christian
García Alcaide, Felipe
Esteban, Mariano
Keywords: VIH (Virus)
Vacunes antivíriques
Cèl·lules T
HIV (Viruses)
Viral vaccines
T cells
Issue Date: 6-Nov-2015
Publisher: Public Library of Science (PLoS)
Abstract: Trial Design: Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable viremia. Thirty participants were randomized (2:1) to receive either 3 intramuscular injections of MVA-B vaccine (coding for clade B HIV-1 Env, Gag, Pol and Nef antigens) or placebo, followed by interruption of HAART. Methods: The magnitude, breadth, quality and phenotype of the HIV-1-specific T cell response were assayed by intracellular cytokine staining (ICS) in 22 volunteers pre- and post-vaccination. Results: MVA-B vaccine induced newly detected HIV-1-specific CD4 T cell responses and expanded pre-existing responses (mostly against Gag, Pol and Nef antigens) that were high in magnitude, broadly directed and showed an enhanced polyfunctionality with a T effector memory (TEM) phenotype, while maintaining the magnitude and quality of the pre-existing HIV-1-specific CD8 T cell responses. In addition, vaccination also triggered preferential CD8+ T cell polyfunctional responses to the MVA vector antigens that increase in magnitude after two and three booster doses. Conclusion: MVA-B vaccination represents a feasible strategy to improve T cell responses in individuals with pre-existing HIV-1-specific immunity.
Note: Reproducció del document publicat a:
It is part of: PLoS One, 2015, vol. 10, num. 11, p. e0141456
Related resource:
ISSN: 1932-6203
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
693527.pdf1.47 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons